Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: 0.30 + vaccine + web  Related to the article below (Last Update: 8/5/2008)

Taipei shares close weaker on US data, local currency fall - UPDATE
華富財經, Hong Kong - Aug 4, 2008
The tourism sector was down 5.75, the electronics dropped 0.02 pct, while the financial was up 0.32 pct and textile up 0.30 pct. ...
Great Basin Gold Ltd.: Underground Infill Drilling at the ...
MarketWatch -
In addition, this hole intersected 1.2 ft (0.37 m) grading 0.30 oz/t (10.2 g/t) Au and 0.70 oz/t (25.0 g/t) Ag from 147.0-148.3 ft (44.8-45.2 m), ...GBN
Northern Foods says person connected to CEO Barden buys 55555 ...
Trading Markets (press release), CA -
The company said following the purchase, Stefan Barden is now interested in about 1.39 million shares in the company, or 0.30 percent of its issued share ...LON:NFDS - OTC:CMTX
Pioneer Reports Second Quarter 2008 Results
MarketWatch -
... 66073 ========== ========= =========== ========= Basic earnings per share: Income from continuing operations $ 1.33 $ 0.30 $ 2.42 $ 0.53 Income from ...
Puget Energy Reports Second Quarter 2008 Financial Results
WELT ONLINE, Germany -
... net 0.03 Puget Energy?s second quarter 2008 earnings from PSE $ 0.30 Puget Energy?s second quarter merger transaction expenses and other (0.04 ) Puget ...PSD
MOD-PAC CORP. Reports Second Quarter 2008 Results
MarketWatch -
... (0.16) $ (0.37) $ (0.30) $ (0.59) Diluted loss per share: $ (0.16) $ (0.37) $ (0.30) $ (0.59) Weighted average diluted shares outstanding 3430 3450 3438 ...MPAC
German shares TFN at a glance outlook
Forbes, NY - Aug 1, 2008
At 8:10 am, the DAX 30 index was indicated to open around 56 points higher at 6423.79. On Thursday, the DAX closed up 19.44 points, or 0.30 percent, ...
Coventry cuts offset rates by up to 0.30%
Mortgage Solutions, UK - Jul 29, 2008
Coventry is to reduce the rates on its offset range by up to 0.30% from Thursday. The new products include a 6.39% Flexx for Term with no early repayment ...

Canoe.ca
Sloppy defense costs Jurrjens, Braves
Atlanta Journal Constitution,  USA -
The rookie right-hander had an ERA of 0.30 during his four-start road streak, and, truth be told, he pitched better Monday than his line indicated. ...
begins at: 10:15 PM ET USA Today
all 275 news articles »
Endeavour Announces Record Revenues and Cash Flow
FOXBusiness -
Estimated Average Production (A) Daily Production (boepd) 8600 to 9000 Differentials (B) Oil ($/bbl) $(4.00) to $(5.00) Gas ($/mcf) $(0.30) to $(0.40) Gas ...
Cimarex Reports Second-Quarter 2008 Earnings of $2.68 per Share PR Newswire (press release)
all 23 news articles »  XEC - END - WAR:CFL
Source: Google News

THE IMMUNISATION OF CHICKENS AGAINST INFECTIOUS AVIAN ENCEPHALOMYELITIS -
HA Westbury, B Sinkovic - Australian Veterinary Journal, 1976 - Blackwell Synergy
... 0.16 2 0.14 0.42 -+ 0.24 1.86 2 0.29 2.20 f 0.30 2.14 2 0.31 2.08 2 ... This suggested
that wing web vaccination could induce an immune response in some birds, but ...
-

Quantification of the effect of vaccination on transmission of avian influenza (H7N7) in chickens -
JA van der Goot, G Koch, MCM de Jong, M van Boven - Proceedings of the National Academy of Sciences, 2005 - National Acad Sciences
... information on the PNAS web site). The protein homology of the immunogenic part
of the (HA1) between the challenge strain H7N7 and the H7N1 vaccine was 98% and ...

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy -
L Fong, Y Hou, A Rivas, C Benike, A Yuen, GA … - Proceedings of the National Academy of Sciences, 2001 - National Acad Sciences
... Cryopreserved PBMCs obtained before or after vaccination were thawed and analyzed
in ... donors were assessed with the same methodology and had 0.30% ? 0.18% and ...

Functional status is a confounder of the association of influenza vaccine and risk of all cause … -
LA Jackson, JC Nelson, P Benson, KM Neuzil, RJ … - International Journal of Epidemiology, 2006 - IEA
... Search for citing articles in: ISI Web of Science (1). ... that was further from the
null (towards a greater vaccine effect) (OR, 0.45; 95% CI, 0.30?0.68) than ...

[PDF] Decision trees and fuzzy logic: A comparison of models for the selection of measles vaccination … -
L Ohno-Machado, R Lacson, E Massad - Proc AMIA Symp, 2000 - amia.org
... 3 0.70 0.50 0.30 0.40 4 0.40 0.40 0.30 0.40 5 ... A model-based design of a vaccination
strategy against ... Distributed decision support using a web-based interface ...
-

Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS … -
EP Gurfinkel, R Leon de la Fuente, O Mendiz, B … - European Heart Journal, 2004 - Eur Soc Cardiology
... nonfatal myocardial infarction, or severe ischaemia?occurred in 11% of the patients
in the vaccine group vs 23% (relative risk 0.51; 95% CI 0.30 to 0.86; P ...

… and quantitative antibody responses to a nonavalent pneumococcal conjugate vaccine (PncCV) in HIV …
SA Madhi, H Kayhty, L Kuwanda, A Holm, KP Klugman - Int Conf AIDS, 2004 - gateway.nlm.nih.gov
... PncCV or placebo at a mean age (SD) of 1.56 (0.30)months, 2.63 (0.52)m and 3.73
(0.88)m. Antibody concentrations to each of the 9 vaccine serotypes using ...
-

Serologic Hepatitis B Immunity in Vaccinated Health Care Workers -
C Barash, MI Conn, AJ DiMarino, Jr, J Marzano, ML … - Archives of Internal Medicine, 1999 - Am Med Assoc
... Web browser does not support basic Web standards ... date was known were immunized
4.80?0.30 years prior ... On average, group A received 2.91?0.04 doses of vaccine. ...

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and … -
HR SHINEFIELD, S BLACK, P RAY, IH CHANG, NED LEWIS … - The Pediatric Infectious Disease Journal, 1999 - pidj.org
... 3.7% (P = 0.30); and tenderness, 15.5 vs. ... and whole cell diphtheria-tetanus
toxoids-pertussis vaccine in infancy ... regular updates can be found on the Web page ...

Response to Smallpox Vaccine in Persons Immunized in the Distant Past -
SE Frey, FK Newman, L Yan, RB Belshe - JAMA, 2003 - Am Med Assoc
... samples collected prior to vaccination and between 3 and 5 days after vaccination,
6 and ... point titers were determined based on a once daily cut-off of 0.30 nm. ...

Source: Google Scholar

Vaccine improves event-free survival for leukemia patients

 

ATLANTA - Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

Immune response to the PR1 vaccine was associated with an 8.7 month event-free survival compared with 2.4 months for non-responders. Clinical responses ranging from improvements in blood counts to complete cytogenetic remission were observed in 36 percent of the responders compared with 10 percent of non-responders.

"We did not expect dramatic responses in this clinical trial, and were pleasantly surprised to see the clinical responses and improved event-free survival" says Muzaffar Qazilbash, M.D., associate professor in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy.

The Phase I/II clinical trial that ran from 2000 to 2006 was designed to assess the vaccine's safety and its ability to elicit an immune response. Toxicity was limited to low-grade injection site side effects such as redness, swelling and some pain.

The PR1 vaccine is derived from two myeloid leukemia-associated antigens, proteins that are either overexpressed or aberrantly expressed in cancer cells. When PR1 elicits an immune response, PR1-specific cytotoxic T lymphocytes are produced that selectively kill three types of leukemia - myelodysplastic syndrome, acute myelogenous leukemia and chronic myelogenous leukemia.

Out of 66 patients in the trial, 53 had active disease and 13 were in remission when they entered the trial. Of the 53 with one of the three types of active leukemia, 25 (47 percent) had an immune response and 28 did not. Nine out of 25 responders (36 percent) had some type of clinical response compared with three of the 28 non-responders (10 percent).

Among the 13 in remission at the start of the trial, four remained in remission for a median time of 30.5 months.

In phase I trials, patients have been heavily pretreated with other therapies. "We had good accrual and a reasonably long follow-up of almost three years," Qazilbash says, "For a Phase I/II, that's a fair number of patients."

"Immunotherapy works best for low level of disease," Qazilbash says. "So patients with low leukemia burden may get the maximum benefit."

###

Disease-specific Phase II clinical trials of the vaccine for chronic myelogenous leukemia and myelodysplastic syndrome are planned or under way at M. D. Anderson. The Vaccine Company, which makes the PR1 vaccine, is conducting a national Phase III clinical trial for acute myelogenous leukemia.

To be eligible for PR1, patients must be positive for a specific major histocompatibility molecule, HLA-A2. The molecule presents antigens so they can be "seen" by T lymphocytes. Qazilbash says about 40 percent of the general population is HLA-A2+.

The PRI vaccine was developed by Jeffrey Molldrem, M.D., professor in M. D. Anderson's Department of Stem Cell Transplantation. Molldrem co-founded The Vaccine Company in 2003 and the company licensed the technology from M. D. Anderson in 2004. M. D. Anderson has an equity interest in the Vaccine Company. These arrangements are managed in accordance with M. D. Anderson's conflict of interest policies.

Co-authors with Qazilbash and Molldrem are Eric D. Weider, Ph.D., Rosa L. Rios, Sijie Lu, Ph.D., Shreya Kant, Sergio Giralt, M.D., Krishna Komanduri, M.D., and Richard Champlin, M.D., all of the Department of Stem Cell Transplantation and Cellular Therapy; Peter F. Thall, Ph.D., and Xuemei Wang, of M. D. Anderson's Department of Biostatistics; and Elihu H. Estey, M.D., of Jorge Cortes, M.D., M. D. Anderson's Department of Leukemia.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.